Boston Scientific (NYSE:BSX) is facing multiple new securities class action lawsuits tied to disappointing earnings, lowered sales guidance, and a Class I recall of its AXIOS Stent and Delivery ...
The U.S. Food and Drug Administration (FDA) said it is aware that Boston Scientific Corporation (NYSE: BSX) has alerted customers to remove certain AXIOS stents and electrocautery-enhanced delivery ...
Add Yahoo as a preferred source to see more of our stories on Google. Boston Scientific's headquarters is in Marlborough, Massachusetts. (Courtesy of Boston Scientific) This story was originally ...
FDA flags safety risk with Boston Scientific stents after reports of deployment issues causing deaths and injuries, prompting a Class I recall.
Boston Scientific (NYSE:BSX) announced a Class I recall of its AXIOS Stent and Electrocautery-Enhanced Delivery Systems due ...
Boston Scientific Corp BSX on Wednesday initiated the removal of certain AXIOS Stents and Electrocautery-Enhanced Delivery Systems from clinical settings following reports of deployment complications ...
Boston Scientific is running a clinical study titled “A Prospective Multi-Center, Single-Arm Study of Endoscopic Ultrasound-Guided Gastroenterostomy With Lumen-Apposing Metal Stent for Gastric Outlet ...
(HealthDay News) – The AXIOS Stent and Delivery System has been approved by the U.S. Food and Drug Administration to treat pancreatic pseudocysts, the FDA said in a news release. The AXIOS stent is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results